Synedgen Partnership with the University of New South Wales Receives Australian Research Council (ARC) Grant
- Grant will fund understanding of
the biochemical and biophysical structure of the endothelial glycocalyx -
- Synedgen’s CEO, Shenda Baker, gave a related keynote lecture at the Pan Pacific Connective Tissue Societies Symposium on November 25, 2020 -
CLAREMONT, Calif. (BUSINESS WIRE) Synedgen, a biotechnology company using glycopolymer chemistry to develop drugs that enhance and control signaling in the innate immune system, today announced that UNSW in partnership with Synedgen has been awarded an A$600,633, 3-year, research grant from the Australian Research Council (ARC) to advance knowledge of the biochemical and biophysical structure of the endothelial glycocalyx. The resulting study will be the first to explore how charged glycopolymers interact with the endothelial glycocalyx with the goal of mapping the lifecycle of the network of membrane-bound proteoglycans a